Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures. Revenues are now expected to be between $95 million and $100 million, compared with the previous range of $109-$114 million.
OptimizeRx Q1 Earnings Call Highlights
OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics and other macroeconomic pressures.
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.08 per share a year ago.
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
OPRX edges past GDRX with AI-driven platform momentum, stronger estimates and lower valuation despite near-term revenue headwinds.
